HEPLISAV-B Post Marketing Surveillance Study
The primary objective of this post-marketing observational surveillance study is to compare the occurrence of acute myocardial infarction (AMI) in recipients of HEPLISAV-B with recipients of another hepatitis B vaccine. The study will also evaluate the incidence of new onset immune-mediated diseases, herpes zoster, and anaphylaxis in recipients of HEPLISAV-B compared to recipients of another hepatitis B vaccine.